What's hot

View all perspectives
What's Hot

It’s Not Just the Mom, It’s the Dad, Too! Dr. Jonathan Kay

Rheumatoid arthritis in either partner can affect fertility and pregnancy outcomes. Dr. Kay discusses abstract OP0210, abstract OP0212 and abstract OP0211 presented at the virtual EULAR meeting. 

Watch video →
RheumNow Podcast square

RheumNow Podcast - Best of EULAR 2021

Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.

Read more →
audience learn

EULAR 2021 - Day 3 Report

Here are a few notable presentations from this past Friday, Day 3 of the EULAR 2021 virtual meeting.

Read more →

The PsA SpA Paradox of Choice: Dr. Rachel Tate

Dr. Rachel Tate reviews Dr. Laura Coates' presentation Personalized Treatment Strategies in Psoriatic Arthritis, given at the virtual EULAR 2021 meeting. 

Watch video →

Did I Forget Something? Dr. Jonathan Kay

Dr. Jonathan Kay examines abstracts OP0216 and OP0215 that were presented at the virtual EULAR 2021 meeting. 

Watch video →

2021 GRAPPA Treatment Guidelines for Adult PsO & PsA Patients: Dr. Rachel Tate

Dr. Rachel Tate discusses the evidence-based GRAPPA treatment recommendations (abstract OP0229) presented at the virtual EULAR 2021 meeting. 

Watch video →
RheumNow Podcast square

RheumNow Podcast - EULAR 2021 & EULAR-IQ (6.4.21)

Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.

Read more →

RA and Cancer: Myth or Reality? Dr. Jonathan Kay

Dr. Jonathan Kay reviewed highlights from the "Oncorheumatology: the crossroads of cancer and musculoskeletal diseases" scientific session including abstract  OP0187, presented Thursday at the virtual EULAR 2021 meeting.

Watch video →

Psoriatic Arthritis Highlights from EULAR21: Dr. Jack Cush

Dr. Jack Cush reviews two abstracts presented at the virtual EULAR 2021 meeting: abstract OP0010 (Efficacy and Safety of Faecal Microbiota Transplantation for Active Peripheral Psoriatic Arthritis: A Randomised Sham-Controlled Trial) and abstract LB0004 (Efficacy and Safety of Secukinumab in Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis: Primary Results from a Randomised, Double-Blind, Placebo-Controlled, Treatment Withdrawal, Phase 3 Study [JUNIPERA])

Watch video →

Do Patients on Upadacitinib Need Labs? Dr. Janet Pope

Dr. Janet Pope discusses abstract OP00128, "Integrated Laboratory Abnormality Profiles of Upadacitinib with up to 4.5 Year of Exposure in Patients with Rheumatoid Arthritis Treated in the Select Phase 3 Program", presented at the virtual EULAR 2021 meeting.

Watch video →

How to Measure Success in Lupus? Dr. Kathryn Dao

Dr. Kathryn Dao discusses abstract OP0296, "The 2021 DORIS Definition of Remission in SLE - Final Recommendations From an International Task Force", presented at the virtual EULAR 2021 meeting.

Watch video →

A Triple Header of RA Plenary Abstracts: Dr. Jonathan Kay

Dr. Jonathan Kay reviews three RA abstracts from the opening plenary session at the EULAR 2021 virtual meeting: abstract OP0012; abstract OP0007; and abstract OP0006.       

Watch video →

PROs in Spa and PSA: Dr. Rachel Tate

Dr. Rachel Tate reviews two abstracts - OP0051 and OP0049 - presented at the virtual EULAR 2021 meeting.

Watch video →
      RT @Janetbirdope: ILD in RA is a killer! @eular_org abst OP0099 Admin day from France claims database. ILD was clinicall

      Janet Pope Janetbirdope

      4 years 5 months ago
      ILD in RA is a killer! @eular_org abst OP0099 Admin day from France claims database. ILD was clinically dx in 2.5% & had 3X mortality. Low prevalence compared to some studies of 6% so maybe worst cases but Impt cause of excess death in RA @RheumNow @eular_org @jeffsparks https://t.co/mPfpPSHxsd
      RT @uptoTate: The post hoc EXCEED analysis showed similar efficacy of SEC and ADA with respect to enthesitis burden. Wha

      Dr. Rachel Tate uptoTate

      4 years 5 months ago
      The post hoc EXCEED analysis showed similar efficacy of SEC and ADA with respect to enthesitis burden. What drug class do you choose as first line therapy for your PsA patients with prominent enthesitis? #EULAR2021 @RheumNow
      RT @uptoTate: Dr. Angioni et al characterize PsA clinical remission on a molecular level. c-FOS and CCD50 (YMER) appear

      Dr. Rachel Tate uptoTate

      4 years 5 months ago
      Dr. Angioni et al characterize PsA clinical remission on a molecular level. c-FOS and CCD50 (YMER) appear to be two key genes. #EULAR2021 poster #POS0409 @RheumNow https://t.co/4lytsgjdzj https://t.co/ySjIXBHTA0
      RT @uptoTate: Does it matter if you diagnose a symptomatic pt w/ nr-axSpA vs r-axSpA? (2/2) Interestingly there are smal

      Dr. Rachel Tate uptoTate

      4 years 5 months ago
      Does it matter if you diagnose a symptomatic pt w/ nr-axSpA vs r-axSpA? (2/2) Interestingly there are smaller deltas between ASAS40 results in PBO vs nr-axSpA compared to axSpA vs PBO in MEASURE 2, PREVENT, COAST-V, COAST-X, RAPID, C-axSpAnd. Dr. Deodhar #EULAR2021 @RheumNow https://t.co/V8zlZdGltQ
      RT @KDAO2011: "50% of time spent in LLDAS = 50% less damage accrual"- Prof E Morand reviews data on low disease activity

      k dao KDAO2011

      4 years 5 months ago
      "50% of time spent in LLDAS = 50% less damage accrual"- Prof E Morand reviews data on low disease activity state in lupus https://t.co/FU3hPvuyRU
      RT @KDAO2011: Prof Van Vollenhoven reveals the Definition of Remission in SLE (DORIS 2021): treating SLE to target #EULA

      k dao KDAO2011

      4 years 5 months ago
      Prof Van Vollenhoven reveals the Definition of Remission in SLE (DORIS 2021): treating SLE to target #EULAR2021 @rheumnow 👉SLEDAI=0 👉MD global<0.5 👉dsDNA, C3/C4 does not matter 👉prednisone <=5 mg/d, stable meds 👉remission can be met at any point (duration not required https://t.co/TwusJkXR19
      RT @uptoTate: Does it matter if you diagnose a symptomatic patient with nr-axSpA vs radiographic axSpA? (1/2)Dr. Deodhar

      Dr. Rachel Tate uptoTate

      4 years 5 months ago
      Does it matter if you diagnose a symptomatic patient with nr-axSpA vs radiographic axSpA? (1/2)Dr. Deodhar discusses differences in tx withdrawal/dose reduction(PBO) shown in RE-EMBARK, ABILITY-3, C-OPTIMISE. #EULAR2021 @RheumNow https://t.co/wVYsPYFLAi
      RT @Janetbirdope: MUC5B variant gene in 5634 RA pts had 2X ⬆️ risk of RA ILD - same gene as in IPF. Clinical relevan

      Janet Pope Janetbirdope

      4 years 5 months ago
      MUC5B variant gene in 5634 RA pts had 2X ⬆️ risk of RA ILD - same gene as in IPF. Clinical relevance is unknown but could it result in a novel Rx pathway? ? Effect of sex & smoking @RheumNow @eular_org abst OP0007 #EULAR2021 https://t.co/8XpKjPFfUX
      RT @Janetbirdope: To clot or NOT? Real world data usually show no ⬆️ VTE in RA with #Jaki compares to other advanced

      Janet Pope Janetbirdope

      4 years 5 months ago
      To clot or NOT? Real world data usually show no ⬆️ VTE in RA with #Jaki compares to other advanced therapies. Diff from high CV risk pts in Oral Surveillance where Tofacitinib had higher VTE vs TNFi @AbbVie symposium @eular_org #EULAR2021 @RheumNow Hard to reconcile diff risk. https://t.co/AWY2zZPSIb
      RT @uptoTate: Dr. Deodhar reviews ASAS imaging/clinical classification and defines nrAxSpA at #EULAR2021 ⁦@RheumNow⁩

      Dr. Rachel Tate uptoTate

      4 years 5 months ago
      Dr. Deodhar reviews ASAS imaging/clinical classification and defines nrAxSpA at #EULAR2021 ⁦@RheumNow⁩ https://t.co/OdlQvGyNfY
      RT @KDAO2011: Introducing EULAR's new name: 'European Alliance of Associations for Rheumatology' highlighting the import

      k dao KDAO2011

      4 years 5 months ago
      Introducing EULAR's new name: 'European Alliance of Associations for Rheumatology' highlighting the importance of collaboration in the scientific community and bringing the patient’s voice across all bodies of work #EULAR2021 @rheumnow
      RT @Janetbirdope: Andrew Ostor @AbbVie symposium @eular_org presented HZ vaccines are safe in RA pts with #JAKi but with

      Janet Pope Janetbirdope

      4 years 5 months ago
      Andrew Ostor @AbbVie symposium @eular_org presented HZ vaccines are safe in RA pts with #JAKi but with Recombinant HZ vaccine humeral response - 75% in RA pts in JAKi vs 100% controls. So should we hold JAKi with Shringix & if so for 1 or 2 wks? #EULAR2021 @RheumNow https://t.co/wVOFMa9fLm
      RT @Janetbirdope: Lifetime risk of HZ is 30%! ⬆️ in pts with immune diseases or immunesuppression. All #JAKI ⬆️

      Janet Pope Janetbirdope

      4 years 5 months ago
      Lifetime risk of HZ is 30%! ⬆️ in pts with immune diseases or immunesuppression. All #JAKI ⬆️ risk maybe doubling but NNH & NNT give context. UPA Rx in active RA -20 more pts in remission vs 1 excess HZ if comparing UPA to ADA in RA @RheumNow #EULAR2021 AbbVie symposium https://t.co/14i0IsIpzs
      RT @Janetbirdope: Do you think JAKi cause VTE? @eular_org @RheumNow #EULAR2021

      Janet Pope Janetbirdope

      4 years 5 months ago

      Do you think JAKi cause VTE? @eular_org @RheumNow #EULAR2021

      RT @Janetbirdope: Do you think #JAKI ⬆️ #MACE cardiovascular events vs TNFi? @eular_org @RheumNow #EULAR2021

      Janet Pope Janetbirdope

      4 years 5 months ago

      Do you think #JAKI ⬆️ #MACE cardiovascular events vs TNFi? @eular_org @RheumNow #EULAR2021

      Catch up on Conference Podcasts

      ×